Statin therapy is associated with reduced total and cardiovascular mortality after coronary artery bypass grafting surgery

Coronary Artery Disease

Volumn 19, Issue 8, 2008, Pages 619-625

  Papathanasiou, Athanasios ^a   Toumpoulis, Ioannis K ^a   Milionis, Haralampos J ^a   Kalantzi, Kallirroi ^a   Katsouras, Christos S ^a   Goudevenos, John ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cardiovascular disease mortality; Coronary artery bypass grafting surgery; Statin therapy; Total mortality

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; STATIN;

ADULT; AGED; ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL;

AGED; CARDIOVASCULAR DISEASES; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; FEMALE; GREECE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 56849116721     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3283142607     Document Type: Article

References (22)

1. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomized trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344:563-570.
2. Domanski MJ, Borkowf CB, Campeau L, Knatterud GL, White C, Hoogwerf B, et al. Prognostic factors for atheroclerosis progression in saphenous vein grafts. J Am Coll Cardiol 2000; 36:1877-1883.
3. Lazar HL. Role of statin therapy in the coronary bypass patient. Ann Thorac Surg 2004; 78:730-740.
4. Cavender JB, Rogers WJ, Fisher LD, Gersh BJ, Coggin CJ, Myers WO. Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up. CASS Investigators. J Am Coll Cardiol 1992; 20: 287-294.
5. Sabik JF 3rd, Blackstone EH, Gillinov AM, Smedira NG, Lytle BW. Occurrence and risk factors for reintervention after coronary artery bypass grafting. Circulation 2006; 114:1454-1460.
6. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-1009.
7. Hueb W, Gersh BJ, Costa F, Lopes N, Soares PR, Dutra P, et al. Impact of diabetes on five-year outcomes of patients with multivessel coronary artery disease. Ann Thorac Surg 2007; 83:93-99.
8. Toumpoulis IK, Anagnostopoulos CE, Balaram S, Swistel DG, Ashton RC Jr, DeRose JJ Jr. Does bilateral internal thoracic artery grafting increase long-term survival of diabetic patients? Ann Thorac Surg 2006; 81:599-606; discussion 606-597.
9. Flaker GC, Warnica JW, Sacks FM, Moyé LA, Davis BR, Rouleau JL, et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and recurrent events CARE investigators. J Am Coll Cardiol 1999; 34:106-112.
10. Werba JP, Tremoli E, Massironi P, Camera M, Cannata A, Alamanni F, et al. Statins in coronary bypass surgery: rationale and clinical use. Ann Thorac Surg 2003; 76:2132-2140.
11. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N Engl J Med 1997; 336:153-162.
12. White CW, Gobel FL, Campeau L, Knatterud GL, Forman SA, Forrester JS, et al. Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial. Circulation 2001; 104:2660-2665.
13. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. Jama 1990; 264:3013-3017.
14. Collard CD, Body SC, Shernan SK, Wang S, Mangano DT. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2006; 132:392-400.
15. Pan W, Pintar T, Anton J, Lee VV, Vaughn WK, Collard CD. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 2004; 110:1145-1149.
16. Dotani MI, Elnicki DM, Jain AC, Gibson CM. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 2000; 86:1128-1130; A1126.
17. Papathanasiou A, Milionis H, Toumpoulis I, Kalantzi K, Katsouras C, Pappas K, et al. Smoking cessation is associated with reduced long-term mortality and the need for repeat interventions after coronary artery bypass grafting. Eur J Cardiovasc Prev Rehabil 2007; 14:448-450.
18. American Academy of Family Physician. Family Practise Management-October 1998: ICD-9 codes for Family Practise: 1998-1999. Available at: www.aafp.org/fpm/981000fm/icd9.html.
19. Goudevenos JA, Papadimitriou ED, Papathanasiou A, Makis AC, Pappas K, Sideris DA. Incidence and other epidemiological characteristics of sudden cardiac death in northwest Greece. Int J Cardiol 1995; 49:67-75.
20. Campeau L, Enjalbert M, Lesperance J, Bourassa MG, Kwiterovich P Jr, Wacholder S, et al. The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med 1984; 311:1329-1332.
21. Klyachkin ML, Davies MG, Svendsen E, Kim JH, Massey MF, Barber L, et al. Hypercholesterolemia and experimental vein grafts: accelerated development of intimal hyperplasia and an increase in abnormal vasomotor function. J Surg Res 1993; 54:451-468.
22. Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 2000; 102:157-165.